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Abstract
Continuous gradients exist at osteochondral interfaces, which may be engineered by applying
spatially patterned gradients of biological cues. In the present study, a protein-loaded microsphere-
based scaffold fabrication strategy was applied to achieve spatially and temporally controlled
delivery of bioactive signals in three-dimensional (3D) tissue engineering scaffolds. Bone
morphogenetic protein-2 and transforming growth factor-β1-loaded poly(D,Llactic- co-glycolic
acid) microspheres were utilized with a gradient scaffold fabrication technology to produce
microsphere-based scaffolds containing opposing gradients of these signals. Constructs were then
seeded with human bone marrow stromal cells (hBMSCs) or human umbilical cord mesenchymal
stromal cells (hUCMSCs), and osteochondral tissue regeneration was assessed in gradient
scaffolds and compared to multiple control groups. Following a 6-week cell culture, the gradient
scaffolds produced regionalized extracellular matrix, and outperformed the blank control scaffolds
in cell number, glycosaminoglycan production, collagen content, alkaline phosphatase activity,
and in some instances, gene expression of major osteogenic and chondrogenic markers. These
results suggest that engineered signal gradients may be beneficial for osteochondral tissue
engineering.
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Spatial patterning of biological cues is vital to some of the most fundamental aspects of life,
from embryogenesis, to wound healing, to nerve cell signaling; all involve concentration
gradients of signaling molecules. Gradient-based signal delivery strategies have so far
gained the most attention in the fields of neural tissue engineering11,15,27 and in the study of
chemotaxis.10,29 Continuous gradient-based bioactive signal delivery systems have seldom
been applied in the area of interfacial tissue regeneration. While various strategies have been
developed to create gradients of bioactive signals (see review47), a major limitation with
many of these techniques is that they allow the delivery of only haptotactic cues via gel-
based substrates. Integration of controlled release technology with graded- signal delivery
from macroporous polymeric scaffolds may be a valuable tool in regenerative medicine.
Moreover, such interfacial tissue engineering strategies also address a biomimetic approach
towards tissue regeneration, where regeneration of a tissue may be enhanced by the presence
of endogenous signals provided by the neighboring tissue.18 Furthermore, using gradients of
multiple bioactive factors, multiple tissue regeneration can be addressed via a single cell
source, where, for example, stem cells can be differentiated along different lineages within
the same constructs.
From the perspective of osteochondral tissue engineering, an in vitro study reported that
only co-culture with chondrocytes (as opposed to fibroblasts or osteoblasts) was successful
at promoting osteogenic differentiation of mesenchymal stem cells in a selective manner,18
indicating the importance of simultaneous triggering of osteo- and chondro-induction for
osteochondral tissue regeneration. An integrated scaffold with embedded gradients of
growth factors at the interface may trigger simultaneous tissue formation, and may have a
synergistic effect on tissue regeneration. For osteochondral tissue engineering, there are only
a few previous reports of scaffold designs having a heterogeneous distribution of growth
factors embedded within an integrated scaffold.20,23,24 A recent study investigated the
release of bone morphogenetic protein (BMP)-2 and insulin-like growth factor (IGF)-1
inside poly(D,L-lactic-co-glycolic acid) (PLGA) and silk fibroin microspheres, suspended in a
gradient pattern, inside alginate gels.60 Another study reported a gradient-gene delivery
strategy, where a zonal organization of osteoblastic and fibroblastic cellular phenotypes was
engineered in a single construct for the purposes of interfacial tissue engineering. 40 To the
best of our knowledge, continuous gradient-based signal delivery from microparticles alone
has never before been applied in the area of osteochondral tissue engineering.
Microsphere-based tissue engineering scaffold designs have gained increasing interest over
the past few years.39,45,57,60 Utilizing microspheres as the building block of a scaffold offers
several benefits, which include the ease of fabrication, control over morphology and
physicochemical characteristics, and versatility of controlling the release kinetics of
encapsulated factors.5 The properties of a scaffold, in turn, can be tailored by altering the
microsphere design. For example, the pore size and porosity of a scaffold at micro-levels
can be made application-specific by altering the size or changing the interior morphology of
the microspheres. 7,8 Similarly, macromechanical properties and degradability can be altered
with the selection of the raw material. To design biodegradable matrices, PLGA, an aliphatic
α-hydroxy polyester, is one of the most widely used polymers that has been approved for
use in several products. The polymer also offers flexibility in the degradation kinetics,
modulated by altering one or more factors, such as molecular weight, co-polymer ratio,
tacticity, crystallinity, etc.53,61
The goal of the present study was the integration of controlled release technology with a
gradient scaffold fabrication strategy, where microsphere-based scaffolds containing
opposing gradients of chondrogenic and osteogenic factors were fabricated using
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monodisperse protein-loaded microspheres and an ethanol sintering method. TGF-β1 is
widely known for inducing chondrogenesis,14,21,54 as BMP-2 is for osteogenesis. 30,38,54 In
addition, the two proteins can also have mutually inductive effects on differentiation,31,50
such as forming the hypertrophic chondrocyte region at the osteochondral interface. The
current study attempted to employ the different efficacies of the proteins, where endogenous
concentrations of BMP-2 can be several times greater than those used for TGF-β1 during in
vitro studies. A modest BMP-2/TGF-β1 ratio of 2:1 was chosen with future in vivo studies in
consideration, where avoiding systemic toxicity of growth factors will be important. The
constructs were utilized for osteochondral tissue engineering using bone marrow stromal
cells (hBMSCs) and human umbilical cord mesenchymal stromal cells (hUCMSCs). There
is a growing interest in hUCMSCs as a mesenchymal stem cell source, as they have been
shown to have osteogenic, 2,25,28,33,58,65 chondrogenic,2,28,55,59 cardiogenic, 55,62 and
adipogenic2,28,33,62 potential. This study evaluated for the first time the performance of
these cells in simultaneous osteogenic and chondrogenic (osteochondral) differentiation, and
compared their performance to hBMSCs.
MATERIALS AND METHODS
Scaffolding Materials
Poly(D,L-lactide-co-glycolic acid) copolymer (PLGA; 50:50 lactic acid : glycolic acid, acid
end group, MW ~42,000–44,000 Da) of intrinsic viscosity (i.v.) 0.36–0.37 dL/g was
purchased from Lakeshore Biomaterials (Birmingham, AL). Poly(vinyl alcohol) (PVA; 88%
hydrolyzed, 25,000 Da) was obtained from Polysciences, Inc. (Warrington, PA).
Transforming growth factor (TGF)-β 1 and BMP-2 were purchased from Peprotech, Inc.
(Rocky Hill, NJ).
Preparation of Protein-loaded Microspheres
BMP-2 was reconstituted in 10 mg/mL bovine serum albumin (BSA) in phosphate buffered
saline (PBS) (both from Sigma, St. Louis, MO). TGF-β1 was reconstituted in 1 mg/mL BSA
in PBS. The reconstituted protein solutions were individually mixed with PLGA dissolved in
dichloromethane (DCM) (20% w/v) at a loading ratio of 10 ng TGF-β1 or 20 ng BMP-2 per
1.0 mg of PLGA. The final mixture was then sonicated over ice (50% amplitude, 20 s).
Using PLGA-protein emulsions, uniform protein-loaded PLGA microspheres were prepared
using technology from our previous reports.4,49 Briefly, using acoustic excitation produced
by an ultrasonic transducer, regular jet instabilities were created in the polymer stream that
produced uniform polymer droplets. An annular carrier non-solvent stream (0.5% w/v PVA
in doubledistilled water, ddH2O) surrounding the droplets was produced using a nozzle
coaxial to the needle. The emanated polymer/carrier streams flowed into a beaker containing
the non-solvent. Incipient polymer droplets were stirred for 3–4 h to allow solvent
evaporation, which were then filtered and rinsed with ddH2O to remove residual PVA, and
stored at −20 °C (Fig. 1a). Blank control microspheres were prepared in a similar manner,
where the protein solution was replaced with an equivalent volume of BSA solution (1 mg/
mL). Following 48 h of lyophilization, the size distribution of microsphere preparations was
determined using a Coulter Multisizer 3 (Beckman Coulter Inc., Fullerton, CA) equipped
with a 560-µm aperture.
Scaffold Fabrication
Gradient scaffolds were prepared using a technology reported previously.49 Briefly,
lyophilized protein-loaded microspheres were dispersed in ddH2O 2.5% w/v, and separately
loaded into two syringes. Each construct in total contained ~50 mg of microspheres. Thus,
gradient and biphasic scaffolds each contained ~25 mg of BMP-2-loaded polymer, and ~25
mg of TGF-β1-loaded polymer, the only difference being the physical transition between the
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two bioactive signals. The suspensions were pumped into a cylindrical glass mold (5.3 mm
diameter, 3.0 cm in height) in a controlled manner using programmable syringe pumps
(PHD 22/2000, Harvard Apparatus, Inc., Holliston, MA). Using a filter (particle retention >3
µm) at the bottom of the mold, ddH2O was filtered, while the microparticles stacked in the
mold until a height of 2.5 mm was reached (Fig. 1b). The profile for Gradient constructs was
linear, where the transition region from TGF-β1 to BMP-2 constituted the middle half of the
scaffold volume, and the top and bottom quarters contained one growth factor. Using an
additional infusion syringe pump and a vacuum pump, a constant level of distilled water was
maintained in the mold. The stacked microspheres were then sintered using a 100% ethanol
treatment for 1 h.49 The molds (containing the scaffolds) were freeze-dried for 48 h, then the
gradient scaffolds were retrieved and stored at −20 °C. Blank scaffolds and constructs with a
homogenous growth factor content (loaded with either all TGF-β1 or all BMP-2) were
prepared in a similar manner.
Description of Experimental Groups
For constructs with hUCMSCs, six different groups were investigated: (i) blank scaffolds
(no growth factors encapsulated) with microspheres of ~220 µm in diameter, (ii) blank
scaffolds with microspheres of ~70 µm in diameter (to investigate a smaller pore size), (iii)
scaffolds loaded with all BMP-2 (homogeneous, no gradient), (iv) scaffolds loaded with all
TGF-β1 (homogeneous, no gradient), (v) scaffolds with a biphasic (sharp interface)
transition from “osteogenic” (BMP-2-loaded) to “chondrogenic” (TGF-β1-loaded), and (vi) a
gradient transition between microsphere types. Groups (iii) through (vi) used microspheres
with a diameter of ~220 µm. For constructs with hBMSCs, only blank scaffolds were
compared to gradient scaffolds, each with ~220 µm microspheres (Fig. 1c).
Cell Seeding and Culture
hBMSCs (from a 24-year-old, non-smoking male, lot # PCBM1632) at P1, (i.e., plated once)
were purchased from StemCell Technologies (Vancouver, Canada). hUCMSCs were
harvested from umbilical cords (n = 2) as described previously.58 Briefly, human umbilical
cord collection and cell harvests were approved by the University of Kansas Human
Subjects Committee (KU-Lawrence IRB approval # 15402, KU Medical Center IRB
approval # 10951). All cords were collected from the University of Kansas Medical Center
and processed within 24 h. Cords were first cut into 3–5 cm pieces, and then vessels were
removed from each cord segment. Cord segments were minced and incubated in 0.75 mg/
mL type II collagenase (298 U/mg; Worthington Biochemical; Lakewood, NJ) at 37 °C.
After a 5-h incubation, the resulting homogenous gelatinous solution was obtained and
diluted (1:8) in sterile PBS. The solution was centrifuged, the supernatant was discarded,
and cells frozen for future use. Frozen hBMSCs and hUCMSCs were thawed, plated at a
density of 4000 cells/cm2 and cultured. The culture medium for both hBMSCs and
hUCMSCs consisted of Dulbecco’s Modified Eagle medium (DMEM; low glucose), 1%
penicillin–streptomycin (P/S), and 10% fetal bovine serum (FBS-MSC quantified) (all from
Invitrogen Life Technologies, Carlsbad, CA). When 80–90% confluent, the cells were
trypsinized and re-plated at the same plating density. Scaffolds (diameter 5.3 mm, height 2.5
mm) were sterilized using ethylene oxide, and placed in a 48 well plate. For gradient and
biphasic constructs, the osteogenic side was placed on the bottom (i.e., resting on the well
plate surface). It was assumed that orientation would have no significant effect on results.
Cells (P4) were re-suspended at a concentration of 10 × 106 cells/mL. Approximately 28 µL
(50% of the scaffold volume, approximately corresponding to the pore volume49) of cell
solution was placed directly onto the top of the scaffold, which was soaked into the scaffold
via capillary action. Cells were allowed to attach to the scaffolds for 2 h, which was denoted
as “week 0.” Then, 1.5 mLof a defined medium was added and the scaffolds were cultured
statically. Up to day 3, the defined medium consisted of DMEM(low glucose), 1% P/S, 1X
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Insulin-Transferrin-Selenium (ITS)-premix (BD Biosciences, San Jose, CA), 40 µg/ mLL-
proline (Sigma), 100 µM sodium pyruvate (Fisher Scientific, Pittsburgh, PA), and 50 µg/mL
L-ascorbic acid (Sigma). 1.0 mL of the 1.5 mL was refreshed twice daily for the first 3 days.
Following day 3, the defined culture medium was supplemented with 4 mM β-
glycerophosphate (disodium salt, pentahydrate; Calbiochem, San Diego, CA) and 100 nM
dexamethasone. The rationale was that β-glycerophosphate may serve more as a tool for
calcium phosphate deposition by osteoinduced cells rather than as a direct differentiation
signal, and that dexamethasone may facilitate both chondrogenic and osteogenic
differentiation. After day 3, 1 mL of the 1.5 mL was refreshed every 24 h.
Protein Release Profiles
TGF-β1 and BMP-2 release (from assembled scaffolds and an equivalent mass of non-
sintered microspheres) were measured in PBS at 37 °C using enzymelinked immunosorbent
assay (ELISA) kits (BMP-2 from Peprotech Inc. and TGF-β1 from BD Biosciences). To
guarantee no interference between bioactive factors, constructs made from homogeneous
TGF-β1- loaded or homogeneous BMP-2-loaded microspheres (~220 µm diameter) were
used. Samples of PBS surrounding the scaffolds (n = 3) were taken at 12 h, then at 1, 2, 3, 5,
7, 10, 14, and 21 days. Loading efficiencies (n = 3) were determined by combining 10 mg of
either TGF-β1- or BMP-2-loaded microspheres with 50 µL dimethyl sulfoxide (DMSO,
Sigma) and 950 µL of PBS. The samples were vortexed thoroughly, and allowed to sit
overnight. The samples were then centrifuged at 20,000 rpm for 30 min to pellet polymer
fragments, and the supernatant tested via ELISA. This procedure was performed for both
microspheres, and microspheres sintered with ethanol for 1 h. The percent released from
scaffolds and microspheres at each time-point was tabulated compared to the total amount of
detected protein in ethanol-treated, or nonethanol-treated microspheres.
Quantitative Polymerase Chain Reaction
In preparation for RT–PCR, samples (n = 4) at 0 and 6 weeks were first homogenized in 1
mL Trizol reagent (Invitrogen) and the RNA was isolated according to the manufacturer’s
guidelines. Isolated RNA was converted to cDNA using a TaqMan High Capacity kit
(Applied Biosystems, Foster City, CA) in a BioRad ThermoCycler. TaqMan Gene
expression assays from Applied Biosystems for collagen type I (Hs00164004_m1), collagen
type II (Hs00156568_m1), SRY-box 9 (Sox9, Hs00165814_m1), bone sialoprotein (BSP,
Hs00173720_m1), runt-related transcription factor 2 (Runx2, Hs00231692_m1), secreted
phosphoprotein 1 (SPP1 or osteopontin, Hs00959010_m1), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, Hs99999905_m1) were used in conjunction with an Applied
Biosystems 7500 Fast Real-time PCR System. A 2−ΔΔ Ct method was used to evaluate the
relative level of expression for each target gene.32 For quantification, the hUCMSC Blank
220 constructs were designated as a calibrator group, and GAPDH expression as an
endogenous control.
Biochemical Analyses
Constructs (n = 4) were analyzed for matrix production using biochemical assays at 0, 3, and
6 weeks. At week 0, only hUCMSC Blank 220, Blank 70, and hBMSC Blank 220 scaffolds
were analyzed for biochemical content. First, a digestion solution consisting of 125 µg/mL
papain (from papaya latex, Sigma), 5 mM N-acetyl cysteine, 5 mM
ethylenediaminetetraacetic acid (EDTA), and 100 mM potassium phosphate buffer (20 mM
monobasic potassium phosphate, 79 mM dibasic potassium phosphate in ddH2O) in ddH2O
was mixed (all reagents from Sigma). Constructs were removed from culture in a sterile
manner, placed in microcentrifuge tubes, homogenized with the papain mixture, and allowed
to digest overnight in a 60 °C water bath. The digested scaffolds were then centrifuged at
10,000 rpm for 5 min to pellet fragments of polymer and other impurities, and stored at −20
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°C. Later, the supernatant was used to determine DNA, glycosaminoglycan (GAG), and
hydroxyproline (HYP) content. DNA content was quantified using the Picogreen assay
(Molecular Probes, Eugene, OR) according to the manufacturer’s instructions. A conversion
factor of 8.5 pg/cell, based on earlier preliminary studies, may be used to convert DNA
content to cell number. GAG content was measured using a dimethylmethylene blue
(DMMB) assay as recommended by the vendor (Biocolor, Newtownabbey, Northern
Ireland). Alkaline phosphatase (ALP) activity was determined at 0, 1, 2, 3, and 6 weeks, and
expressed as a measure of liberated p-nitrophenol concentration/µg protein/min, as described
elsewhere.9 Net HYP content was assessed using a modified hydroxyproline assay16 as
described in our previous publications.59 A conversion factor of 11.5 can be used to convert
HYP mass to collagen mass based on our preliminary studies. In the cases of GAG and HYP
content, results for overall biochemical production and normalized content were analyzed.
Histological Staining
At 3 and 6 weeks, samples (n = 3) were allowed to equilibrate at 37 °C in optimal cutting
temperature embedding medium (OCT, Tissue-Tek) overnight, then frozen at −20 °C,
sectioned at 14 µm parallel to the construct axis (Fig. 2) using a cryostat, and collected on
SuperFrost Plus slides (Fisher Scientific). Safranin-O/Fast Green staining for GAGs and
Alizarin Red staining for calcium deposition was done as described elsewhere.1 Slides were
then dehydrated in graded alcohol and cleared in xylene for mounting.
Mechanical Testing
Mechanical characterization of the constructs (n = 4) was performed using a uniaxial testing
apparatus (Instron Model 5848, Canton, MA, 50 N load cell) under unconfined compression.
Tare-loaded (0.05 N) constructs were compressed to 15% strain at a rate of 1% per second
under PBS (138 mM sodium chloride, 2.7 mM potassium chloride) at 37 °C, followed by
stress relaxation at 15% strain for 30 min. Moduli of elasticity were obtained from the linear
regions of the stress–strain curves. Relaxed moduli were calculated as the ratio of the final
stress value (at the end of 30 min) to the step strain. The stress was defined as the ratio of the
load to the initial crosssectional area, and the strain was defined as the ratio of the change in
the length to the original length.49 Mechanical testing was performed on hBMSC Blank
constructs at week 0, and on hBMSC Blank and Gradient constructs at week 6. It was
assumed that growth factor incorporation would not have a detectable effect on mechanical
properties or tissue formation at week 0, thus the Gradient was only tested at 6 weeks.
Statistical Analyses
Statistical analyses were performed using a single factor analysis of variance (ANOVA) in
SPSS/PASW 17.0 software (SPSS Incorporated, Chicago, IL), followed by a Tukey’s
Honestly Significant Difference post hoc test when significance was detected below the p =
0.05 value. All quantitative results (numerical values and representative diagrams) were
expressed as the average ± standard deviation.
RESULTS
Microspheres and Scaffold Fabrication
Protein-loaded microspheres having uniform diameter were created using the previously
reported Precision Particle Fabrication method.4 The microspheres displayed high
monodispersity, with a ~220 µm nominal diameter for all of the three types of microspheres
prepared: BMP-2 loaded “osteogenic” microspheres, TGF-β1 loaded “chondrogenic”
microspheres, and control “blank” microspheres (Fig. 3). Specifically, microsphere sizes in
the range of ~220 µm were chosen, as it was our hypothesis that pore sizes commensurate
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with this range may be more conducive to cellular infiltration and matrix production. To
evaluate this hypothesis, a negative control scaffold exhibiting a smaller pore size
(microsphere diameter ~70 µm) was incorporated into the hUCMSC culture (Fig. 3).
Cylindrical gradient scaffolds containing opposing gradients of chondrogenic and osteogenic
factors along the axis of the molds were produced,49 along with other positive control
groups (homogeneously-loaded TGF-β1 and BMP-2), and scaffolds with a biphasic (sharp)
transition from osteogenic to chondrogenic (Fig. 1c). The final scaffolds were 5.3 mm in
diameter, and 2.5 mm in height, making the scaffold volume ~55 µL. The porosity of the
scaffolds, as determined by previous investigations,49 is typically about 41%, as measured
by µCT image reconstruction, with pore sizes ranging from 20–120 µm.49 The scaffolds
were then seeded with hBMSCs and hUCMSCs and cultured for a 6-week duration as
described previously.
Protein Release
TGF-β1 and BMP-2 protein release from scaffolds were monitored for 21 days with ELISA
as an approximate indication of the temporal delivery profile. In addition, protein release
from microspheres alone was observed to contextualize the effects of ethanol sintering on
PLGA during construct fabrication. The loading efficiencies for TGF-β1 and BMP-2
microspheres were 16.4 ± 1.7% and 15.4 ± 3.0%,respectively. The loading efficiencies for
TGF-β1 and BMP-2 microspheres treated with ethanol for 1 h were 7.55 ± 0.58% and 5.5 ±
1.5%. After day 1, scaffold formulations had an accelerated rate of release compared to
microspheres alone, with up to 20% of the entrapped protein being liberated by 21 days (Fig.
4).
Gene Expression
All hBMSC and hUCMSC groups expressed BSP during week 0, although there were no
statistically significant changes between treatments. hBMSC Blank constructs demonstrated
a 35-fold (p < 5 × 10−5) higher level of expression over the calibrator group (hUCMSC
Blank 220), which was indeed significant. BSP expression was not detectable in any
experimental group after 6 weeks of culture (data not shown).
Expression of collagen type II was detected in all hBMSC and hUCMSC constructs at week
0, although there were no statistically significant changes between treatments. Collagen type
II expression was not abundant in any of the experimental groups after week 0 (data not
shown).
Throughout the culture period, expression of collagen type I was evident in all constructs.
Among hUCMSC groups, there were not statistically significant differences between groups
or throughout the culture period (Supplemental Fig. 1a). Once again, hBMSCs clearly
demonstrated a change in collagen type I expression (Fig. 5a). At week 6, hBMSC Blank
220 constructs showed an increase in gene expression of 1.9 times more than the week 0
value (p < 5 × 10−8) and 6.2 times the hUCMSC Blank 220 constructs at week 6 (p < 0.05).
hBMSC Gradient scaffold expression at week 6 was 1.5 times higher than the hBMSC
Blank 220 value at the same time point (p < 5 × 10−4), 9.9 times greater than the hUCMSC
Blank 220 group at 6 weeks (p < 5 × 10−11), and 3.1 times higher than the hBMSC Gradient
value at week 0 (p < 5 × 10−11).
Osteopontin (OPN) expression was seen in all hBMSC and hUCMSC groups at week 0
(Supplemental Fig. 1b). Among hUCMSC treatments, the only statistically significant
change among groups or during culture was a 4.7-fold loss in OPN expression in the
Biphasic constructs from week 0 to 6 (p < 0.001). OPN expression levels were not evident at
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6 weeks for hBMSC Blank 220 samples, and barely present in hBMSC Gradient constructs
(Supplemental Fig. 1b).
Runx2 expression in hUCMSC groups remained constant (no statistically significant
differences) throughout the culture period (Supplemental Fig. 1c). Results for the hBMSC
Gradient group were quite the opposite, with expression levels 11.7 times higher than the
hUCMSC Blank 220 constructs at week 6 (p < 0030.001) and 3.6 times greater than hBMSC
Blank 220 groups at week 0 (p < 0.05) (Fig. 5b).
Like Runx2, Sox9 expression was not significantly different among all hUCMSC groups
from week 0 to week 6 (Supplemental Fig. 1d). In contrast to the hUCMSC groups, Sox9
expression in the hBMSC groups increased over the course of 6 weeks (Fig. 5c). hBMSC
Gradient constructs at 6 weeks demonstrated a 31–fold higher gene expression compared to
hUCMSCBlank 220 scaffolds at week 6 (p < 5 × 10−5), had a 9.5-fold greater expression
than hBMSC Blank 220 constructs at week 0 (p < 5 × 10−5), and a 3.8-fold higher
expression compared to hBMSC Blank 220 constructs at week 6 (p < 0.005).
DNA Content
The overall DNA content for all hUCMSC and hBMSC constructs at least doubled during
the 6-week culture period compared to week 0 (Fig. 6). All growth factor-loaded scaffolds
had statistically significant increases in DNA content from week 3 to week 6 (p < 0.05), and
hUCMSC Chondrogenic, Biphasic, and Gradient scaffolds displayed a higher mean DNA
content (~61–83% more) per construct compared to the blank scaffolds at 6 weeks (p <
0.05). Detailed statistics can be found in Supplementary Table 1.
Glycosaminoglycan Content
The overall GAG content for all constructs increased at least 3 times during the 6-week
culture period compared to week 0 (p < 5 × 10−6), with this increase also being statistically
significant between weeks 3 and 6 (p < 1 × 10−5) (Fig. 7a). At 6 weeks, only hUCMSC
Gradient and Biphasic constructs had statistically greater GAG levels (~50% more) than
hUCMSC Blank scaffolds at week 6 (p < 0.05). Detailed statistics for the net GAG content
can be found in Supplementary Table 1.
The normalized data indicated other significant differences in the treatment groups (Fig. 7b).
At week 0, hUCMSC Blank 70 constructs made significantly less GAG/DNA than the
hUCMSC Blank 200 group (p < 0.01). At 3 weeks, hUCMSC Blank 220, Chondrogenic,
and Biphasic constructs made less GAG/ DNA than during week 0 (p < 0.001), but the
Blank 220 and Blank 70 increased GAG/DNA production by week 6 (p < 0.05). In addition,
hUCMSC Gradient constructs made more GAG/DNA (7.5 times greater) at week 3 than
hUCMSC Blank 220 constructs (p < 1 × 10−4). GAG/DNA output on hBMSC groups did
not change significantly during the study. According to the normalized data, by 6 weeks,
GAG/DNA production on all hUCMSC and hBMSC constructs were not significantly
different from each other.
Hydroxyproline Content
Although HYP content was not evident in hUCMSC constructs at week 0, it was present by
week 3 for all groups, but only the hUCMSC Blank 220, Blank 70, and Gradient constructs
demonstrated a significant increase (p < 0.05) (Fig. 8a). By 6 weeks, all hUCMSC
constructs, except the Chondrogenic group, showed statistically significant increases in HYP
content compared to week 0 (p < 0.005). At 6 weeks, hUCMSC Gradient constructs
demonstrated ~2 times more HYP production than the hUCMSC Blank and Biphasic groups
(p < 0.01), at least 3 times more than hBMSC Blank and Gradient constructs (p < 0.001),
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and at least 2 times more than any other group at 6 weeks (p < 0.01). HYP production for the
hBMSC constructs did not differ significantly between treatments or between time points.
Detailed statistics for the net HYP content can be found in Supplementary Table 1.
Normalized data indicated other significant differences in the treatment groups. By 3 weeks,
hUCMSC Blank 220, Blank 70, and Gradient constructs made more HYP/DNA than the
previous time point (p < .05), but Gradient constructs were the only ones to make
significantly more HYP/DNA than the control at that time (p < 0.01) (Fig. 8b). hBMSC
constructs demonstrated a more defined pattern, with an increase in HYP/DNA production
at week 3 (p < 5 × 10−6), and a subsequent decrease at week 6 (p < 5 × 10−5). hBMSC
Gradient constructs also produced 2 times less HYP/DNA at week 3 than the hBMSC Blank
220 constructs (p < 5 × 10−7).
Alkaline Phosphatase Activity
ALP activity for all hUCMSC and hBMSC constructs showed no statistically significant
changes until week 3 (Fig. 9). ALP activity at week 3 for hUCMSC Biphasic scaffolds was
15 times larger than the week 0 value (p < 1 × 10−4), 6.5 times larger than the previous week
(p < 0.001), and was 1.8 times greater than hUCMSC Blank constructs at week 3 (p < 0.05).
At week 6, hUCMSC Biphasic scaffolds had greater ALP activity compared to the control at
week 6 (p < 0.01). The hUCMSC Gradient group also demonstrated a statistically significant
increase overall between week 0 and week 6 (p < 0.005). It was also noted that ALP activity
of the hUCMSC constructs exhibited high standard deviations, compared to hBMSCs
scaffolds.
Histological Staining
Staining for GAG content with Safranin-O/Fast Green, and Alizarin Red for calcium
deposition, was done on identical areas of constructs to most accurately analyze
characteristics of dual tissue and matrix formation. Supplementary Figure 3a shows tissue
formation after 3 weeks of culture in hUCMSC microsphere-based scaffolds. At 3 weeks, all
hUCMSC constructs demonstrated some degree of GAG staining near the top, with
Osteogenic and Chondrogenic scaffolds having more intense staining in the top region. In
addition, Biphasic and Gradient scaffolds appeared to be indiscernible from Blank 220 and
Blank 70 scaffolds, with sparse GAG staining located on the top of the scaffold. Cell nuclei,
visualized with Harris Hematoxylin, were distributed evenly throughout most constructs,
with the exception of the Blank 70 group, which lacked a large cell population inside of the
microsphere scaffold. At 3 weeks, hBMSC constructs showed overall staining, arguably less
than hUCMSC Blank 220 and Blank 70 scaffolds (Supplemental Fig. 3b). Interestingly, the
location of calcium staining at 3 weeks within the hUCMSC constructs correlated strongly
with location of GAG staining, but was also present throughout the rest of the constructs.
Nodules of calcium staining, however, were most prominent in the hUCMSC Osteogenic
group.
By 6 weeks, GAG and calcium staining in hUCMSC constructs was significantly greater
than observed at 3 weeks, such that the perimeters of the once-present microspheres were
clearly visible within the matrix, with faint counter-staining filling the void space (Fig. 10a).
Osteogenic and Gradient groups exhibited large, non-uniform clusters of GAG staining near
the top of the constructs, while Blank 220 and Biphasic groups had minimal GAG staining.
The Chondrogenic group exhibited nodules of GAG staining throughout the entire construct,
while GAG staining in the Blank 70 constructs was less than any other group. As observed
at 3 weeks, calcium staining associated heavily with location of glycosaminoglycan staining,
but was also evident in other areas of the constructs. Perhaps the most striking representation
of a gradient transition between types of tissue matrix was seen in the hBMSC scaffolds at 6
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weeks (Fig. 10b). hBMSC Blank 220 constructs exhibited uniform calcium staining and
little GAG staining, whereas hBMSC Gradient constructs had light GAG staining localized
to the top and dissipated towards of the center of the construct.
Mechanical Testing
Following unconfined compression testing, the modulus of elasticity was determined to be
127 ± 44 kPa for the constructs at week 0 (Supplemental Fig. 2). This value dropped
drastically after 6 weeks of culture to 3.3 ± 1.4 kPa for Blank constructs and to 4.0 ± 0.4 kPa
for Gradient constructs. Similarly, the relaxed moduli decreased from 2.1 ± 0.8 kPa at week
0 to 1.1 ± 0.6 kPa for Blank constructs and to 0.9 ± 0.2 kPa for Gradient constructs. The
elastic moduli between Blank and Gradient constructs at week 6 were not statistically
different. The same was true for the relaxed moduli between the two groups after the culture
period had concluded.
DISCUSSION
The primary objective of this study was to evaluate the dual signaling with bioactive factors,
in the form of a microsphere-based gradient, to address osteochondral interfacial tissue
engineering. To the best of our knowledge, this was the first effort to examine simultaneous
osteogenic and chondrogenic differentiation of hUCMSCs and hBMSCs on continuously
graded 3D scaffolds for interfacial tissue engineering.
A specialized cell culture media was carefully formulated, based on the current literature for
inducing chondrogenesis2,28,55 and osteogenesis.2,28,33,43,62 The circumstances in this
experiment, however, were novel in that both of these pathways were being addressed
simultaneously, something that is not well characterized. The most logical approach was to
ensure that the defined media included essential components for differentiation into either
cell type.
The results also confirmed that microsphere degradation released both BMP-2 and TGF-β1
in a temporal manner (Fig. 4). A classic “burst” release of protein, common to microsphere-
based delivery,4,5 was observed in the first week, allowing delivery of up to ~20% of total
entrapped protein from scaffolds by 21 days, during a crucial time when differentiation of
the seeded cells was taking place. Most importantly, release most likely extended well
beyond this time frame for continuous signal delivery, judging by the onset of third phase of
release typically seen in PLGA microparticle delivery.3 The accelerated release rate of
ethanol-treated microspheres, when compared to microspheres alone, suggests that polymer
chain entanglement was altered during sintering. In previous investigations with this
design,49 it was shown that ethanol treatment lowered the PLGA glass transition
temperature from 41.04 ± 0.17 °C to 33.98 ± 0.09 °C. Moreover, at 37 °C the scaffolds
might have exhibited a diminished ability to sequester protein. In addition, the lower
entrapment efficiency observed for sintered microspheres was most likely due to a certain
fraction of protein near the microsphere surfaces being exposed to ethanol. Ideal endogenous
growth factor concentrations may be different from the values achieved during this first
attempt, and the need for future investigation of varying loading values will be warranted.
Lastly, during cell culture, media was refreshed more frequently than during the release
study, thus, the quantity of endogenous growth factors in the well during culture may have
varied slightly from the observed release profile. Coupled with an osteochondral medium,
many primary factors contributing to osteogenic and chondrogenic differentiation were
addressed during culture.
In the current study, major osteogenic and chondrogenic markers were monitored for an
indication of how gene expression changed due to dual signal delivery. At week 0, all
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groups expressed collagen I, collagen II, BSP, OPN, Runx2, and Sox9. Perhaps this can only
be taken as an indication of the multi-lineage potential of hBMSCs and hUCMSCs. Gene
expression in hBMSCs in general was more pronounced than in hUCMSCs. By 6 weeks,
BSP and collagen II were not in enough abundance to detect in both hUCMSCs and
hBMSCs. During osteogenesis, many genes, including BSP, have fluctuating expression.
BSP is most known as a primary non-collagenous protein of mineralized tissues,6,42 and if
there were to be formation of a bonelike tissue taking place, the absence of BSP at later
times may be nothing more than an indication that the matrix is not nearing late-term.
Similarly, collagen II is associated with hyaline cartilage,51 thus there only may have been
some degree of chondrogenic differentiation.
Statistically, there were no differences in the gene expressions of collagen I, Runx2, and
Sox9 during the study (Supplemental Fig. 1). Average OPN expression remained unchanged
in most hUCMSC and all hBMSC constructs during the culture period, with only one
statistically significant decrease, in the hUCMSC Biphasic group (Supplemental Fig. 1b).
Initially, this phenomenon seemed counterintuitive, as in some groups osteoblastic-like
behavior was desired, with OPN being an extracellular structural protein in bone.42 Recent
characterizations of hUCMSCs have shown that the umbilical cord stroma has a baseline
OPN expression,25 and OPN expression during culture may actually significantly decrease
in hUCMSCs, regardless of whether receiving an osteogenic treatment. 56 It has also been
suggested that OPN acts in later stages of remodeling by tethering osteoclasts to the
mineralized matrix,12,41 a phase (bone resorption) that these constructs had not reached.
In some instances, however, hBMSCs clearly demonstrated that a gradient in bioactive
signaling had advantages in promoting expression of both osteogenic and chondrogenic
markers (Fig. 5). Being the most abundant of the collagens, a statistically significant
increase in collagen I alone (from a growth-factor loaded construct) is not necessarily cause
for excitement, but coupled with key transcription factors for osteoblast (Runx2) and
chondrocyte (Sox9) differentiation 19 at later culture times, warrants a closer look at the
potential of a gradient in bioactive signaling. In this instance, hBMSCs are most likely the
superior model for changing gene expression due to the gradient design. This does not
necessarily imply that hUCMSCs lack expression of any key osteogenic and chondrogenic
markers, just that hBMSCs perhaps tailor a more well-understood quantitative response to
growth factor delivery coupled with defined culture conditions. Tests to compare primer
sensitivity were not performed in this study, however, previous investigations in
osteogenic56,58 or chondrogenic59 differentiation of hUCMSCs, with RT–PCR techniques
and probes identical to the ones used in this study, have not indicated significant detection
errors. Future characterizations, including more frequent monitoring of gene expression
early in culture, might better delineate the transitory expression of specific genes during
differentiation. In addition, including more donors for both hUCMSCs and hBMSCs might
minimize variation.
Based on DNA content (Fig. 6), and a conversion factor of 8.5 pg DNA/cell, a cell seeding
efficiency of 55% (hUCMSCs) to 70% (hBMSCs) was calculated. Thus, there appears to be
room for improvement with regard to cell attachment, and methods such as functionalizing
the polymer with Arg-Gly-Asp (RGD) residues22,63,64 may help. Yet, DNA content saw
multiple-factor increases by week 6. By 6 weeks, hUCMSC Chondrogenic, Biphasic, and
Gradient groups were the only groups with significantly higher cell content than the control;
however, the three treatments were not significantly different from each other. In addition,
even though an increase in cell number alluded to proliferation and cell retention, these
results alone did not prove proliferation. Moreover, at this time, dual growth factor inclusion
could not be misconstrued as a means to definitively increase cell number.
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Overall GAG formation was initially slow to take place in all groups, with statistically
significant increases only by the last week of culture (Fig. 7a). Only the dual growth factor
groups (hUCMSC Biphasic and Gradient) outperformed their control at that time,
suggesting that chondrogenesis may have been enhanced in the presence of both TGF-β1 and
BMP-2. The normalized GAG data showed interesting trends (Fig. 7b). The difference in
GAG content per cell between hUCMSC Blank 70 and hUCMSC Blank 220 constructs
suggested that a smaller pore size had an effect on some instances of biochemical
production, possibly due to the different physical proximities of the cells that had managed
to penetrate the scaffold. In addition, the Gradient design might have had advantages in
promoting early biochemical output from cells, judging by the increased GAG per cell at
week 3. Thus, perhaps only the Gradient design was beneficial for constant increased GAG
output per cell, as Blank constructs had fluctuating GAG per cell output. In addition, it
appears that hBMSCs were not as sensitive to the Gradient design, as both groups
maintained the same level of GAG production during the entire study.
Net HYP content in hUCMSC groups increased at week 3 for the Blank 220, Blank 70, and
Gradient groups, with the Osteogenic and Biphasic groups having increased HYP mass at
week 6. (Fig. 8a). Because hUCMSCs Chondrogenic constructs failed to have an increase in
HYP content during the whole culture, and at 6 weeks, the level was less than the control,
the collagen composition might have been different from the other treatment groups. In
addition, hUCMSC Blank 220, Blank 70, Osteogenic, and Biphasic constructs were not
different from one another with regard to HYP content, and all were significantly less than
hUCMSC Gradient constructs in HYP content, at 6 weeks. The normalized data
demonstrated a similar advantage of the Gradient constructs, with hUCMSCs in these
groups producing at least 2 times more HYP than the Blank 220 and Biphasic groups at 3
weeks (Fig. 8b). The finding of net HYP content at 6 weeks, and HYP content per cell at 3
weeks, being significantly higher in the Gradient constructs than in the Biphasic and Blank
220 constructs was among the most important findings of the current study. The Gradient
and Biphasic groups had exactly the same relative numbers of osteogenic and chondrogenic
microspheres, but a different spatial organization. Therefore, this significant difference in
HYP content demonstrated that taking the same signals and releasing them in opposing
gradients, instead of in two adjacent homogeneous regions, could result in a significant
improvement in early and overall biosynthesis. Moreover, gradient-based strategies may be
beneficial for osteochondral tissue engineering where early neosynthesis of tissue is critical
for defect healing and construct integration.
As mentioned, there were no statistically significant changes in ALP activity in hUCMSC or
hBMSC scaffolds up until week 3 (Fig. 9). Because ALP isoforms are present in many tissue
types,37 having baseline p-nitrophenol activity in hUCMSCs alone (as in the Blank 220 and
Blank 70 constructs) is not surprising. Yet, at 3 weeks and 6 weeks, the hUCMSC Biphasic
group showed a statistically significant increase over the control. It is known, however, that
during osteogenic differentiation of MSCs, ALP activity decreases at later times, as it is an
early indicator of osteogenic differentiation.26 The absence of statistically significant
decreases in ALP activity in the treatment groups suggests that either osteogenic
differentiation might not have taken place yet, or this phenomenon was missed due to
spacing between assay time points. Interestingly, an unchanging ALP activity in osteogenic
differentiation of hUCMSCs has been observed before,56 thus, the reasons for such a
discrepancy should be investigated further.
Based on histology, it appeared that having a smaller pore size, as in the hUCMSC Blank 70
group, hindered cellular penetration within the microsphere matrix. Even though this group
performed satisfactorily during biochemical production, the majority of this matrix formed
around the perimeter of the constructs. In addition, the inclusion of growth factors in general
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appeared to enhance both GAG formation and calcium deposition. GAG formation
sometimes occurred in small nodes on the top side of the scaffold, rather than evenly
throughout the construct. Furthermore, a small amount of tissue production in hUCMSC
constructs might be localized to the side of the scaffold that cell seeding took place, not
necessarily to growth factor location, despite most constructs (with the exception of the
hUCMSC Blank 70 group) having cell penetration throughout the scaffolding (Fig. 10). In
addition, calcium deposition overlapped with GAG formation on the scaffold tops, but was
also present throughout the constructs in places where GAGs were not. The significant
calcium deposition in most hUCMSC constructs (along with collagen I expression) could be
consistent with recent evidence suggesting that hUCMSCs may be predisposed toward the
osteoblast lineage.13 Uniform exposure of β-glycerophosphate and dexamethasone may have
contributed to calcium staining observed throughout the constructs, however, uniform
exposure of β-glycerophosphate (or any other culture medium component) would not be an
issue as this technology translates to in vivo application. Strategies such as changing the
TGF-β1/BMP-2 loading ratio, improving protein stability, or changing polymer degradation
rate, may improve the results. In hBMSC Blank 220 constructs, there was little GAG
formation, and evenly distributed calcium deposition. In contrast to hUCMSC scaffolds,
hBMSCs readily demonstrated a histological response to the gradient of growth factors,
having light GAG formation near the top of the construct, which faded as it approached the
middle. Visualization of a gradient in tissue underscored the importance of improving and
refining this technology.
The drastic drop in the mechanical integrity of the constructs was most likely a consequence
of microsphere degradation that led to the disappearance of the sintering sites with time,
transitioning to the mechanical integrity of the neo-synthesized tissue (Supplemental Fig. 2).
To improve the mechanical stiffness of the constructs, one method could be to utilize
microspheres with encapsulated nanomaterials such as calcium carbonate (CaCO3),17,48
titanium dioxide (TiO2),34,48,52 or hydroxyapatite (HAp). The inclusion of HAp, especially
in vivo, may also enhance osteoblastic behavior and osseointegration as seen in other tissue
engineering35,36,44 and microsphere45,46 applications. As of now, the focus on
comprehensive tissue regeneration is of utmost importance, but later in development, in
clinical cases where osteochondral defects are large, mechanical stiffness will become a
substantial priority, and the gradient strategy described here will be highly conducive to
incorporating stiffness gradients as well, as recently outlined.48
Lastly, we acknowledge that the gradients cannot be sustained for a long duration in the in
vitro culture environment, and released growth factors in soluble form will eventually
diffuse unless they are consumed by the cells. To maintain the gradient profiles during the
culture, the media was refreshed twice a day for first 3 days (a crucial period for cell
differentiation) and then daily afterwards. This unconventional media refreshment frequency
was applied to mitigate the effects of growth factor diffusion and maintain the spatial
profiles of growth factors during the in vitro culture period. One can envision that growth
factor diffusion will be a lesser concern in vivo, where diffusion of the factors will be
restrained in a confined environment (as in the case of a defect repair) and in the absence of
cell culture media. Follow-up in vivo work will give insight about this hypothesis.
Future work should include evaluation of higher growth factor concentrations, surface
functionalization Osteochondral Interface Tissue Engineering 2179 for cell attachment, and
accelerated scaffold degradation. Given that the current study was a proof of concept for the
feasibility of the approach and the large-scale effects on the entire scaffolds, gradient
transitions were monitored only histologically. With evidence from histology and total
collagen content suggesting that gradients have the potential to improve efficacy and lead to
regionalized tissue formation, examination of regional biochemical content,
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immunohistochemistry, and gene expression will be warranted in the future.19 In situ
hybridization will also allow visualization of region-specific gene expression, as tracking
cell populations will be instrumental in refining the spatiotemporal characteristics of the
gradient for hUCMSCs, hBMSCs, and other stem cell types.
CONCLUSION
One must consider the progression of these two stem cell types toward the desired lineages,
with hBMSCs starting further along in their “journey” to produce bone and cartilage matrix
and express the proper osteoblast and chondrocyte phenotypes. Consequently, the response
to growth factors and culture conditions is cell-specific. With the data presented here, it was
clear that both cell types had their distinct strengths. The hBMSC response to the Gradient
design in protein signaling was well defined within their gene expression, but the actual
biochemical performance by hBMSCs was not especially significant compared to
hUCMSCs. Yet, biochemical activity from hUCMSCs came with larger variations between
samples, and their ability to meaningfully localize the significant matrix produced was
inferior to hBMSCs, which indicated that further investigation will be needed to more
accurately control hUCMSC differentiation. Cellular idiosyncrasies aside, the merit of using
macroscopic gradients for osteochondral interfacial tissue engineering in vitro was
demonstrated in many key ways. With the proof-of-concept established here, it may stand to
reason that the gradient-based scaffolds will be well suited for in vivo application, with a
support structure to facilitate a continuous transition of bone regeneration to cartilage
regeneration.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Microparticle and scaffold fabrication process. (a) Microspheres were made from a polymer
stream (20% w/v PLGA in DCM) and annular carrier stream (0.5% w/v PVA in ddH2O)
with an ultrasonic transducer; (b) Programmable pumps created a gradient in microsphere
types based on a time-dependent process; (c) Experimental groups and particle sizes for
hBMSCs and hUCMSCs.
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Sectioning and orienting construct slices. Constructs were placed in culture with the
“chondrogenic” side upwards and the “osteogenic” side towards the well plate surface. This
orientation was maintained throughout the harvesting and histological procedure and for
photo orientation.
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Size characterizations for microparticles. Using a multisizer, fabricated particle batches were
checked to confirm size distribution. The average diameter of all larger microspheres was
approximately 220 µm (BMP-2-loaded and Blank 220 Groups ~215 µm, TGF-β1-loaded
~225 µm), while the smaller microspheres measured near 70 µm.
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Protein release from PLGA constructs. Release samples were taken at 12 h, and 1, 2, 3, 5, 7,
10, 14, and 21 days for (a) TGF-β1 and (b) BMP-2 microparticles and scaffolds. Percent
released was calculated from the total amount of detected protein entrapped. Scaffolds
showed an accelerated release profile compared to microspheres, and the onset of the third
phase of release is evident at day 21. Values are reported as mean ± standard deviation, n =
3.
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Gene expression of collagen type I, Runx2, and Sox9 in hBMSC constructs. Gradient
constructs enhanced gene expression of (a) collagen type I, and (c) Sox9 at 6 weeks. Runx 2
expression (b) was not evident in hBMSC Blank 220 constructs at 6 weeks, whereas it was
in Gradient groups. Values are reported as mean ± standard deviation, n = 4. Statistically
significant change of expression @ = over the calibrator (hUCMSC Blank 220) at that time
point (p< 0.05), # = over its value at the previous time point (p < 0.05), and * = over the
control (Blank 220) at that time point (p < 0.05).
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DNA content for all hUCMSC and hBMSC groups at 0, 3, and 6 weeks. All groups had
statistically significant increases over the week 0 cell number by 6 weeks, hUCMSC growth
factor groups and all hBMSC groups had statistically significant increases over the week 3
values, and select hUCMSC growth factor constructs had significantly higher values
compared to the control at 6 weeks (hUCMSC Blank 220). Values are reported as mean ±
standard deviation, n = 4. Statistically significant change @ = over the week 0 value (Blank
220) (p < 0.05), # = over its value at the previous time point (p < 0.05), and * = over the
control (Blank 220) at that time point (p < 0.05).
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GAG content for all hUCMSC and hBMSC groups at 0, 3, and 6 weeks. (a) At 6 weeks, all
groups had statistically significant increases in GAG content over the week 0 and week 3
values. Only hUCMSC Biphasic and Gradient constructs had significantly higher GAG
content compared to the control at 6 weeks. (b) hUCMSC on Blank 70 scaffolds had a
diminished GAG/DNA at week 0, and hUCMSC Gradient constructs had increased GAG/
DNA production over the control at 3 weeks. Values are reported as mean ± standard
deviation, n = 4. Statistically significant change @ = over the week 0 value (Blank 220) (p <
0.05), # = over its value at the previous time point (p < 0.05), and * = over the control
(Blank 220) at that time point (p < 0.05).
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Net hydroxyproline production for all hUCMSC and hBMSC groups at 0, 3, and 6 weeks.
(a) Most hUCMSC groups had statistically significant increases in hydroxyproline from
week 0 to week 6, but only hUCMSC Gradient constructs had significantly higher
production relative to the control at 6 weeks. Notably, this value was at least 2 times higher
than any other group at the end of culture. At 6 weeks, the hUCMSC Chondrogenic group
also showed a statistical decrease in net hydroxyproline compared to the Blank 220 group at
6 weeks. (b) hUCMSC Gradient constructs produced more HYP/DNA than the control at 3
weeks, although by 6 weeks the levels were not different from the control. Values are
reported as mean ± standard deviation, n = 4. Statistically significant change @ = over the
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week 0 value (Blank 220) (p < 0.05), # = over its value at the previous time point (p < 0.05),
* = over the control (Blank 220) at that time point (p < 0.05), and ! = over any other group at
that timepoint (p < 0.05).
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Alkaline phosphatase activity of all hUCMSC and hBMSC constructs at 0, 1, 2, 3, and 6
weeks. Only the hUCMSC Biphasic groups showed increases after week 2. Values are
reported as mean ± standard deviation, n = 4. Statistically significant change @ = over the
week 0 value (Blank 220) (p < 0.05), # = over its value at the previous time point (p < 0.05),
and * = over the control (Blank 220) at that time point (p < 0.05).
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Histological staining (Safranin-O/Fast Green and Alizarin Red) of constructs at 6 weeks.
Orientation is detailed in Fig. 2 (for biphasic and gradient groups, the chondrogenic side is
the top, and the osteogenic side is the bottom). (a) hUCMSC growth-factor constructs
showed significantly more GAG formation and calcium deposition. hUCMSC Gradient
constructs had GAG formation localized to the scaffold top (red arrows). hUCMSC
Osteogenic groups appeared to have more homogenous calcium deposition than any other
group. (b) hBMSC Blank 220 scaffolds had little GAG formation and even calcium
deposition, whereas the Gradient group had light GAG staining localized to the scaffold top,
which dissipated towards the center. Scale bar = 200 µm.
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